ImmuCell (ICCC) Q3 2024 earnings summary

Executive summary

• Product sales grew 11% year-over-year in Q3 2024 and 51% for the nine-month period, driven by strong demand for First Defense and operational recovery following remediation of contamination events.

• Net loss narrowed to $2.7 million for the nine months ended September 30, 2024, compared to $4.6 million in the prior year, reflecting higher sales and improved gross margin.

• Gross margin improved to 27% for the nine months ended September 30, 2024, up from 21% in the prior year, as production stabilized and fixed costs were spread over higher volumes.

• The company is preparing for the controlled launch of Re-Tain®, a novel non-antibiotic mastitis treatment, pending FDA approval and resolution of contract manufacturer inspectional observations.

• At-the-market equity offerings raised $4.1 million through October 30, 2024, supporting working capital, operations, and a strengthened cash position.

Financial highlights

• Q3 2024 product sales reached $6.0 million, up from $5.4 million in Q3 2023; nine-month sales totaled $18.7 million, up from $12.4 million year-over-year.

• Gross margin improved to 26% in Q3 2024 from 23% in Q3 2023; nine-month gross margin rose to 27% from 21% year-over-year.

• Net loss for Q3 2024 was $0.7 million ($0.09/share), compared to $0.9 million ($0.12/share) in Q3 2023; nine-month net loss was $2.7 million ($0.34/share) vs. $4.6 million ($0.60/share) in 2023.

• EBITDA for Q3 2024 was $119,000, compared to $(95,000) in Q3 2023; nine-month EBITDA was $(221,000), up from $(2.3 million) year-over-year.

• Cash and cash equivalents increased to $3.8 million as of September 30, 2024, from $979,000 at year-end 2023.

Outlook and guidance

• Management targets approximately $24 million in product sales for full-year 2024, with focus on stabilizing production, improving process yields, and achieving FDA approval for Re-Tain®.

• Gross margin is expected to improve toward 35% as process yields and production output are optimized.

• Controlled launch of Re-Tain® is planned for early 2026, with initial distribution limited to select dairy farms.

• International regulatory approvals for First Defense® are being pursued to drive further growth.

• Product development expenses are being reduced as Re-Tain® approaches FDA approval, with a goal to lower annual spend to $2 million in 2025.